These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 8622102

  • 1. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of acute lower respiratory tract infections caused by gram-negative organisms.
    Covi M, Velluti G.
    J Chemother; 1995 Jun; 7 Suppl 2():137-42. PubMed ID: 8622102
    [Abstract] [Full Text] [Related]

  • 2. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection.
    Colardyn F.
    J Chemother; 1995 Jun; 7 Suppl 2():129-35. PubMed ID: 8622101
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia.
    Beaucaire G.
    J Chemother; 1995 Jun; 7 Suppl 2():165-73. PubMed ID: 8622107
    [Abstract] [Full Text] [Related]

  • 5. Overview of the efficacy of isepamicin in the adult core clinical trial programme.
    Carbon C.
    J Chemother; 1995 Jun; 7 Suppl 2():79-85. PubMed ID: 8622115
    [Abstract] [Full Text] [Related]

  • 6. A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients.
    Viganò A, Principi N.
    J Chemother; 1995 Jun; 7 Suppl 2():95-101. PubMed ID: 8622117
    [Abstract] [Full Text] [Related]

  • 7. Isepamicin versus amikacin in the treatment of urinary tract infection.
    Sturm W.
    J Chemother; 1995 Jun; 7 Suppl 2():149-54. PubMed ID: 8622104
    [Abstract] [Full Text] [Related]

  • 8. The efficacy and safety of isepamicin compared with amikacin in the treatment of intra-abdominal infections.
    Leal del Rosal P.
    J Chemother; 1995 Jun; 7 Suppl 2():143-8. PubMed ID: 8622103
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of empiric aztreonam and aminoglycoside regimens in the treatment of serious gram-negative lower respiratory infections.
    Bjornson HS, Ramirez-Ronda C, Saavedra S, Rivera-Vázquez CR, Liu C, Hinthorn DR.
    Clin Ther; 1993 Jun; 15(1):65-78. PubMed ID: 8458056
    [Abstract] [Full Text] [Related]

  • 11. An overview of the safety of isepamicin in adults.
    Blum D.
    J Chemother; 1995 Jun; 7 Suppl 2():87-93. PubMed ID: 8622116
    [Abstract] [Full Text] [Related]

  • 12. Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients.
    Herbrecht R, Blaise D, Espinouse D, Leblond V, Sadoun A, Sauvage C, Cordonnier C, Minozzi C.
    J Chemother; 1995 Jun; 7 Suppl 2():103-10. PubMed ID: 8622099
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the efficacy and safety of isepamicin in the treatment of various bacterial infections.
    Petrikkos G, Giamarellou H, Tsagaraki C, Pefanis A.
    J Chemother; 1995 Jun; 7 Suppl 2():161-4. PubMed ID: 8622106
    [Abstract] [Full Text] [Related]

  • 14. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E, 309 Study Group.
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
    Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I.
    Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
    [Abstract] [Full Text] [Related]

  • 16. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN, Micek ST, Reichley RM, Ritchie DJ.
    Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
    [Abstract] [Full Text] [Related]

  • 17. Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series.
    Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A.
    Respir Med; 2009 May; 103(5):707-13. PubMed ID: 19118994
    [Abstract] [Full Text] [Related]

  • 18. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S, Kollaras P, Giannakakis T, Seitanidis B, Kordosis T, Nikolaidis J, Hatzitolios A, Nikolaidis P.
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections.
    Tsai TY, Chang SC, Hsueh PR, Feng NH, Wang JT.
    J Microbiol Immunol Infect; 2007 Dec; 40(6):481-6. PubMed ID: 18087627
    [Abstract] [Full Text] [Related]

  • 20. Ceftazidime versus a combination of amikacin and ticarcillin in the treatment of severe infections.
    Limson BM, Navarro-Almario E, Litam P, Que E, Kua LT.
    Clin Ther; 1988 Dec; 10(5):589-93. PubMed ID: 2856601
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.